Fosamax Plus D Tablet
Product Images NDC 78206-136

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fosamax Plus D (NDC 78206-136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Organon Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Alendronate Sodium Structural Formula (Fosamax Plus D 01)

Chemical structure diagram showing the molecular arrangement of a compound containing phosphate and amine groups. The image likely represents a bisphosphonate related molecule, consistent with the active ingredient alendronate sodium in FOSAMAX PLUS D tablets.*

FDA Label Image

Image Of Cholecalciferol Structural Formula (Fosamax Plus D 02)

Chemical structure diagram of cholecalciferol (Vitamin D3), one of the active ingredients in FOSAMAX PLUS D tablets containing alendronate sodium and cholecalciferol.*

FDA Label Image

Image Of Figure 1 (Fosamax Plus D 03)

A line graph comparing the cumulative incidence percentage over time (up to 36 months) between FOSAMAX and placebo groups. The graph shows two lines: one for placebo and one for FOSAMAX, depicting trends in cumulative incidence across months.*

FDA Label Image

Image Of Figure 2 (Fosamax Plus D 04)

A bar graph titled 'Osteoporosis Treatment Studies in Postmenopausal Women' showing mean percentage increase in bone mineral density (BMD) relative to placebo at three years with FOSAMAX 10 mg/day. It compares results for U.S. and multinational studies across three anatomical sites: lumbar spine, femoral neck, and trochanter. The U.S. bars generally show higher BMD increase than multinational bars, with error bars representing standard error.*

FDA Label Image

Image Of Figure 3 (Fosamax Plus D 05)

A figure showing two line graphs comparing the time course effect of FOSAMAX 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline in postmenopausal women. The left graph represents a U.S. study and the right graph a multinational study, both plotting BMD percent change against time in months over a 36-month period.*

FDA Label Image

Principal Display Panel (70 mg/2800 IU Tablet Blister Pack)

FOSAMAX PLUS D 70 mg/2800 IU tablet packaging label showing alendronate sodium and cholecalciferol as active ingredients. The label indicates a 4-tablet package, with dosage instructions for weekly use. The labeler is Organon LLC, and the product is manufactured by Rovi Pharma Industrial Services in Spain. The packaging includes space for a prescription label and barcode areas.*

FDA Label Image

Principal Display Panel (70 mg/5600 IU Tablet Blister Pack)

FOSAMAX PLUS D 70 mg/5600 IU tablets packaging label showing the front, sides, and back of the carton. Contains alendronate sodium and cholecalciferol. The label includes the dosage form as oral tablets, package count of 4 tablets, and medication guide instructions. The manufacturer is Organon LLC, with manufacturing by Rovi Pharma Industrial Services, Spain. The label notes prescription use, storage instructions, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.